DocketNumber: Docket No. 31395-83
Citation Numbers: 88 T.C. 38, 1987 U.S. Tax Ct. LEXIS 4, 88 T.C. No. 4
Judges: Hamblen
Filed Date: 1/12/1987
Status: Precedential
Modified Date: 11/14/2024
*4
Decedent was the largest single shareholder of G company on the date of his death, owning 381,150 shares, or about 23 percent. This stock was restricted stock under the Federal securities laws. Approximately 6 months after decedent's death, P agreed to sell its block of G company stock to C company for $ 24 per share pursuant to a merger of G and C company.
*39 Respondent determined a deficiency of $ 4,330,651.21 in the Federal estate tax of the Estate of Saul R. Gilford. After concessions, the sole issue for decision is the date of death fair market value of 381,150 shares of Gilford Instrument Laboratories, Inc., common stock owned by Saul R. Gilford at his death.
FINDINGS OF FACT
Some of the facts have been stipulated and are found accordingly. The stipulation of facts, the supplemental stipulations of fact, and attached exhibits are incorporated herein by this reference.
Petitioner is the Estate of Saul R. Gilford. On November 17, 1979, Saul R. Gilford (the decedent) died in a private airplane crash. At the time of his death, decedent's domicile was Oberlin, Ohio. Decedent died testate and Lauren E. Wurster (Wurster) was appointed executor of his estate.
Petitioner's Federal estate tax return was timely filed. The alternate valuation date was not elected. Included within the estate were 381,150 shares of stock in Gilford Instrument Laboratories, Inc. (Gilford). Petitioner's return listed the value of*6 this stock as $ 2,801,452.50, or $ 7.35 per share. In his notice of deficiency, respondent determined that the fair market value of the Gilford stock should be $ 9,147,600, or $ 24 per share.
*40 At the time of decedent's death, Gilford, an Ohio corporation, designed, manufactured, and sold scientific instruments for use in the fields of science, medicine, and industry. Gilford's principal products were automated blood analyzers and spectrophotometers and accessory devices. In 1978, Gilford formed a new wholly owned subsidiary, Gilford Diagnostics, Inc., to manufacture and sell clinical chemistry reagents and related disposable products.
During 1979, Gilford sold and marketed its products in the United States and Canada through direct contact and a sales force of 41 persons. Gilford had wholly owned subsidiaries in England, France, and Germany which serviced these and certain other countries in North Africa, Europe, and Eastern Europe. *7 Gilford's automated blood analyzers, reagents, and small clinical spectrophotometers were purchased primarily by hospitals and medical laboratories. The research market, consisting of university and private foundation biomedical research laboratories, purchased the research spectrophotometers. Gilford faced competition from small companies and companies as large as DuPont. *8 and 1978, are as follows: *41 ASSETS Current assets: 1979 1978 Cash $ 770,763 $ 929,753 Receivables, less allowance for doubtful accounts of $ 140,500 in 1979 and $ 135,300 in 1978 8,717,681 7,879,350 Recoverable Federal and foreign income taxes 549,501 Inventories: Finished products 3,486,791 2,595,568 In-process products 2,384,103 2,697,264 Materials and parts 2,485,668 1,922,327 Service parts 1,428,455 1,274,258 Deferred income taxes 234,200 155,200 Prepaid expenses 263,848 219,111 Total current assets 20,321,010 17,672,831 Property, plant and equipment -- at cost Land and improvements $ 302,717 $ 302,717 Buildings and improvements 3,374,358 3,112,722 Machinery, equipment, and other 5,940,767 5,053,061 Construction in progress 1,575,141 Unexpended construction funds invested by trustee 528,516 Total 11,721,499 8,468,500 Less accumulated depreciation 3,425,322 3,091,849 Property, plant, and equipment net 8,296,177 5,376,651 Other assets 195,294 193,984 Total 28,812,481 23,243,466 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Notes payable 3,252,000 2,399,000 Current portion of long term debt 334,400 173,200 Accounts payable 1,895,000 1,360,771 Accrued expenses: Income taxes 233,083 734,990 Other taxes 268,836 196,557 Salaries and wages 749,406 718,917 Employee benefit plans 507,000 448,000 Other 432,081 393,033 Product and service warranties 275,000 283,000 Unearned service contract revenue 996,000 718,000 Total current liabilities 8,942,806 7,425,468 Long-term debt: Obligations under capital lease 1,670,000 835,000 Other 2,026,500 254,200 Total 3,696,500 1,089,200 Deferred income taxes 314,700 238,700 Shareholders' equity: Common stock without par value authorized 2 million shares; issued and outstanding 1,660,499 in 1979 and 1,636,241 in 1978 $ 249,075 $ 245,436 Additional paid-in capital 3,224,828 2,965,865 Retained earnings 12,384,572 11,278,797 Total shareholders' equity 15,858,475 14,490,098 Total 28,812,481 23,243,466
*9 *42 The 1979 annual report also set forth consolidated statements of income for the same fiscal years:
1979 | 1978 | |
Net sales | $ 31,463,301 | $ 27,099,551 |
Operating costs and expenses: | ||
Cost of sales | 16,518,298 | 13,328,644 |
Selling and administrative expense | 9,937,129 | 7,594,768 |
Research and development expense | 2,292,625 | 2,062,301 |
Total | 28,748,052 | 22,985,713 |
Operating income | 2,715,249 | 4,113,838 |
Other income (expense): | ||
Royalties and commissions | 192,261 | 451,134 |
Interest expense | (431,931) | (212,118) |
Other net | 32,489 | 197,537 |
Other income (expense) net | (207,181) | 436,553 |
Income before taxes on income | 2,508,068 | 4,550,391 |
Provision for taxes on income: | ||
Current | 853,000 | 1,908,000 |
Deferred | (3,000) | 95,000 |
Total | 850,000 | 2,003,000 |
Net income | 1,658,068 | 2,547,391 |
Net income per share (based on the average | ||
number of shares outstanding for each year) | 1.01 | 1.57 |
On October 26 to 28, 1979, the Gilford board of directors held a long-range planning meeting in Maine. The drop in net earnings in 1979 concerned the directors, and the discussions at the weekend meeting centered around finding a solution to*10 the earnings problem and establishing a 5-year planning horizon. The consensus of the directors and decedent in particular was that, while no one wanted a merger of the company, there was agreement that both Gilford's poor performance and poor growth could make Gilford vulnerable to a take-over. As a result, the directors *43 felt that they should set up a profile of a "White Knight" company which could be used as a back-up in a take-over attempt. Any talk concerning a merger was purely hypothetical and of a defensive posture.
Decedent was president and chairman of the board of directors of Gilford. Decedent had held this position continuously since the birth of the company in 1958. At the time of his death, decedent was the largest single shareholder of Gilford, owning 381,150 shares. *11 Gilford had one class of common stock without par value. On November 16, 1979, there were 1,664,472 shares of common stock outstanding. The common stock was registered pursuant to section 12(g) of the Securities and Exchange Act. At the time of decedent's death, the stock was actively traded in the over-the-counter market. End of month Volume Month market price for month December 1978 14-14 1/2 68,317 shares January 1979 15 1/2-16 49,062 shares February 1979 13 7/8-14 3/8 35,571 shares March 1979 15 3/4-16 1/4 63,622 shares April 1979 17 1/2-18 64,678 shares May 1979 14 3/8-14 7/8 51,785 shares June 1979 13-13 1/2 97,772 shares July 1979 13 3/8-13 7/8 64,392 shares August 1979 16 1/2-17 1/4 64,481 shares September 1979 14-15 35,387 shares October 1979 12-12 3/4 50,294 shares November 1979 11 1/2-12 1/2 63,973 shares
*12 On November 16, 1979, a Friday, the common stock of Gilford Instrument closed in the over-the-counter market at a bid price of 11 1/2 and an asked price of 12 1/4. On November 19, 1979, Monday, the stock closed at a bid price of 10 1/4 and an asked price of 11 1/4.
*44 The Gilford board of directors first meeting after decedent's death took place on November 27, 1979. The first item of business was the election of a chairman of the board to fill the vacancy created by decedent's death. At the same time, it was agreed that the Company not solicit any such inquiries or offers and that its primary concern at this point is to maintain and restore the momentum of growth experienced by the Company in recent years. * * * [Emphasis supplied.]
The board planned to meet on December 13, 1979, to discuss the overall state of Gilford's business and future plans.
*13 On December 13, 1979, the board formed a finance committee. The minutes do not reflect any merger discussion.
On December 20, 1979, representatives of Gilford's board of directors contacted Kidder Peabody & Co. (Kidder, Peabody) to evaluate Kidder, Peabody as a potential financial consultant to Gilford. On January 2, 1980, Gilford entered into an agreement with Kidder, Peabody for Kidder, Peabody to evaluate financial alternatives for Gilford. During March 1980, the Gilford board of directors began to seriously consider merging with another company. On May 19, 1980, the Wall Street Journal noted that Gilford was considering all available financial options, including affiliation with another company or remaining independent. Petitioner's block of stock was sold to CorningGlass Works of Corning, New York (Corning Glass), for $ 24 a share pursuant to an agreement entered into by Wurster and Corning Glass dated May 30, 1980. The agreement was submitted simultaneously with the merger proposal to the Gilford board of directors. On May 30, 1980, the board of directors agreed to merge Gilford with Corning Glass if certain conditions were met. This information was publicly reported*14 in the Wall Street Journal on June 2, 1980. On *45 October 10, 1980, the shareholders of Gilford approved the merger with Corning Glass.
On February 15, 1980, prior to the filing of decedent's Federal estate tax return, petitioner retained Allyn A. Joyce (Joyce), senior vice president of Management Planning, Inc., of Princeton, New Jersey, to value decedent's 381,150 shares of Gilford common stock. Joyce submitted his valuation report to Wurster on July 29, 1980.
Joyce's definition of fair market value was the price that a willing buyer would pay a willing seller for the block of Gilford stock, if both buyer and seller were reasonably well informed as to the facts and neither was under any compulsion to act. In order to reach an accurate estimate of the fair market value according to this definition, Joyce examined carefully three characteristics of decedent's stock: (1) Its market price at the date of death; (2) the size of the block of stock; and (3) the restricted nature of the stock.
First, in order to reach a market price for the date of decedent's death, which occurred on a Saturday, Joyce evaluated the market on Friday, November 16, 1979, and on Monday, November 19, *15 1979. Joyce took the mean of each day's quotations and then averaged those mean figures to reach an average of $ 11.31 per share for November 17, 1979. In Joyce's opinion, the market price quotation of $ 11.31 reflected such considerations as the nature of the Gilford business, the economic outlook of the instruments industry, the company's book value, its earning capacity, its dividend paying capacity, and goodwill.
Second, Joyce believed that the entire block of 381,150 shares could not have been sold at the market price of $ 11.31 on November*16 17, 1979. While Gilford was an active stock on the over-the-counter market, Joyce reviewed the annual volume data for Gilford shares and concluded that *46 the market could not absorb a block of this size. *17 Petitioner could sell this stock under three methods: (1) The dribble-out rule;
(1) the size of the issuing company measured by its sales
(2) the size and pattern of its earnings;
(3) the trading market; and
(4) resale agreement provisions
In order to determine the appropriate discount to be applied to petitioner's block of stock, Joyce carefully picked other transactions involving restricted securities which came as close as possible to the Gilford block of stock on the four factors. Because financial institutions do not ordinarily reveal detailed information on their transactions in restricted securities, Joyce carefully examined the restricted over-the-counter stock transactions of investment*18 companies. Joyce found 14 companies with restricted stock transactions which he found comparable with the Gilford stock. *47 company and compared the results to Gilford to reach an accurate discount.
*19 First, Joyce concluded that, on the basis of the size of Gilford as measured by sales, its restricted stock should have a discount of 32 percent. Second, on the basis of Gilford's income and its earnings decline, its restricted stock should have a discount of 30 to 33 percent. Third, Joyce noted that discounts were greatest on restricted stock whose unrestricted counterparts traded over the counter, followed by those with unrestricted counterparts traded on the American Stock Exchange, while discounts for stocks with unrestricted counterparts listed on the New York Stock Exchange were the smallest. Fourth, Joyce analyzed stock price variability and resale agreement provisions and found nothing which would cause him to deviate from a 33-percent discount. Finally, Joyce viewed the stability of stock prices and the state of the market as a whole. *20 Based on all these factors, Joyce concluded that the appropriate discount from the market average quotation of Gilford on November 17, 1979, is 35 percent. *48 ULTIMATE FINDINGS OF FACT
The fair market value*21 of each share of Gilford common stock held by the decedent on November 17, 1979, is $ 7.58, with a total fair market value of $ 2,889,117.
OPINION
Property includable in the gross estate is generally included at its fair market value on the date of the decedent's death.
In general, if there is a market for stocks or bonds, on a stock exchange, in an over-the-counter market, or otherwise, the mean between the highest and lowest quoted selling prices on the valuation date is the fair market value per share or bond. If there were no sales on the valuation date but there were sales on dates within a reasonable period both before and after the valuation date, the fair market value is determined by taking *23 a weighted average of the means between the highest and lowest sales on the nearest date before and the nearest date after the valuation date. The average is to be weighed inversely by the respective numbers of trading days between the selling dates and the valuation date. * * *
*49 However, if actual sales are not available during a reasonable period beginning before and ending after the valuation date,
the fair market value may be determined by taking the mean between the bona fide bid and asked prices on the valuation date, or if none, by taking a weighted average of the means between the bona fide bid and asked prices on the nearest trading date before and the nearest trading date after the valuation date, if both such nearest dates are within a reasonable period. The average is to be determined in the manner described in paragraph (b) of this section.
Finally, in cases where the stock's selling prices or bid and asked prices do not reflect fair market value, then "some reasonable modification of that basis or other relevant facts and elements of value are considered in determining the fair market value."
Where sales at or near the date of death are few or of a sporadic nature, such sales alone may not indicate fair market value. In certain exceptional cases, the size of the block of stock to be valued in relation to the number of shares changing hands in sales may be relevant in determining whether selling prices reflect the fair market value of the block of stock to be valued. If the executor can show that the block of stock to be valued is so large in relation to the actual sales on the existing market that it could not be liquidated in a reasonable time without depressing the market, the price at which the block could be sold as such outside the usual market, as through an underwriter, may be a more accurate indication of value than market quotations. * * * On the other hand, if the block of stock to be valued represents a controlling interest, either actual or effective, in a going business, the price at which other lots change hands may have little relation to its true value.
Thus, in valuing stock which is sold on an active market, the estate tax regulations delineate*25 a three-fold test to determine the fair market value of stock. First, if there is a market on a stock exchange or an over-the-counter market, the regulations look to the selling prices on or within a reasonable period before and after the valuation date. Second, in the absence of actual selling prices, the bid and asked prices are examined. *50 selling prices or the bid and asked prices may be considered. *26 a question of fact, and the trier of fact must weigh all relevant evidence and draw appropriate inferences.
As this case is appealable to the Court of Appeals for the Sixth Circuit, we have endeavored to follow that court's view of the valuation process.
Petitioner asserts that, since decedent's Gilford stock was traded in the over-the-counter market, the fair market value per share should be determined by reference to the market quotations immediately before and after the Saturday on which decedent's death occurred. Additionally, petitioner states that a reasonable modification of the fair market value determined by reference to the market quotations must be made due to two factors: (1) The size of the block of stock and (2) the "restricted" nature of the stock.
On the other hand, respondent asserts that while actual market quotations are generally determinative of fair market value for publicly traded securities, the sale or merger *51 of Gilford to Corning Glass created an abnormal market condition which should control the value of the stock. Respondent contends that the agreement*28 between petitioner and Corning Glass on May 30, 1980, was the culmination of a series of events set off by the decedent's death. Rejecting petitioner's blockage and restricted share discount, respondent asserts that petitioner's block of shares was
In considering and weighing all relevant evidence in the record, we acknowledge that a presumption of correctness attaches to respondent's determination of deficiency.
To rebut respondent's presumption, petitioner must introduce some substantial evidence tending to show that respondent was wrong. Where petitioner has not offered evidence sufficient to rebut respondent's presumption, respondent prevails.
First, we will examine respondent's assertion that the sale or merger of Gilford was foreseeable to petitioner's representatives on November 17, 1979, and, thus, should be conclusive that petitioner's block of Gilford stock could *52 have sold at a substantial premium*30 of $ 24 per share on decedent's death. While the question of fair market value is a question of fact, the criterion to be applied in determining value is a matter of law.
In general, property is valued as of the valuation date on the basis of market conditions and facts available on that date
Serious objection was urged by respondent to the admission in evidence of data as to events which occurred after March 1, 1913 [the valuation date]. It was urged that such facts were necessarily unknown on that date and hence could not be considered. It was apparent that there was a fear that the Board would in reaching its judgment be influenced toward a higher value if it were permitted to see the evidence of increasing value after the date in question. The evidence was nevertheless admitted. It is true that value on March 1, 1913, is not to be judged*32 by subsequent events.
*33 Petitioner argues that post-valuation-date documents are not admissible as evidence in support of a higher valuation of petitioner's stock unless respondent can show their relevance by connecting them to the valuation date. In
It also must be kept in mind that the measure of the tax must be determined according to the situation as it existed on the date of the death of the decedent, and not according to subsequent events, "[tempting] as it is to correct uncertain probabilities by the now certain fact * * *."
However, the Sixth Circuit recognized the holding of
In light of the Sixth Circuit's opinion in
The fair market value is the price at which the property would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell
Respondent is not only overreaching the regulations but is arguing contrary to his
Petitioner relies primarily upon the valuation and testimony of its expert witness, Joyce. Respondent chose not to place in evidence any expert valuation. Neither did respondent have an expert witness testify at trial. Expert opinion is admissible if it will assist the trier of fact to understand evidence that will determine a fact in issue. See
Joyce*42 utilized the mean formula to arrive at the pre-discount market price of $ 11.31 per share on November 17, 1979. As November 17, 1979, fell on a Saturday, Joyce used the mean bid and asked prices on Friday, November 16, and Monday, November 19. As expressly outlined by the regulations, Joyce then took these mean figures and averaged them for a market price of $ 11.31.
First, while the regulations provide for a blockage discount in "certain exceptional cases," petitioner must meet his burden of proof as to the correctness and amount of the blockage discount. Petitioner has failed in this respect. There is no presumption of blockage.
Restricted securities are securities acquired from an issuer in a transaction exempt from the registration requirements of the Federal securities laws. Such a transaction is known as a private placement. Not only do the Federal securities laws compel registration when securities are sold by a company, but also when a person controlling a company sells a substantial block of stock. *46 However, securities acquired in a non-public offering, directly or indirectly from an issuer (including a person who controls the issuer), can be resold in accordance with the requirements of SEC rule 144 by affiliates of the issuer.
In his valuation report, Joyce recognizes the resale problem of restricted securities. While decedent did not have direct control of Gilford by owning more than 50 percent of the outstanding stock, decedent did have indirect control over the company as its largest *47 shareholder and moving force behind its success as its only president. As a result, petitioner would be considered a parent of the issuer and any sale of the Gilford shares not issued in a public offering would be classified as restricted shares.
Petitioner, through Joyce's testimony and valuation report, introduced credible evidence that the average discount for a block of over-the-counter restricted securities of a company with the sales and earnings of Gilford was 33 percent. Joyce carefully followed the procedure which respondent *60 has enunciated in
Although the only restrictive requirement as to comparable corporations specified in the statute is that their lines of business be the same or similar,
In sum, after carefully reviewing the study, the record as a whole, and carefully considering all arguments raised by petitioner and respondent, we conclude that Joyce's report made the most valid stock comparisons possible with respect to restricted stock and that a discount of 33 percent is appropriate.
While respondent argues that petitioner's block of stock is more valuable than its mean quotation price, he offered no evidence of a proper premium to be applied to the stock. Except for the blockage discount, we find that petitioner has introduced sufficient evidence to establish a prime facie case. Thus, the burden of going forward*53 with the evidence, but not the burden of proof, shifts to the respondent.
Finally, in closing, we think it pertinent to allude to an observation we recently made concerning adamant and overzealous contentions in valuation disputes which fail to consider the inherent imprecision of value determinations and, consequently, denigrate the settlement process as noted in
*55 To reflect the foregoing,
1. Foreign sales representatives provided a sales force for approximately 55 other countries abroad. Gilford had 30 distributors in the United States and Canada to sell reagents and instruments.
Gilford's subsidiaries were as follows:
State or country | Percentage of | |
Name of subsidiary | of incorporation | voting securities |
Gilford Instruments Ltd. | England | 100% |
Gilford Europe, S.A. | France | 100 |
Gilford Instruments GmbH | Germany | 100 |
Gilford Diagnostics, Inc. | Ohio | 100 |
Gilford Instruments International, Inc. | Ohio | 100 |
PTR Optics Corp. | Ohio | 100 |
PTR Optics International, Inc. (1) | Massachusetts | 100 |
PTR Optics Ltd. (2) | England | 100 |
(1) Wholly owned subsidiary of PTR Optics Corp.
(2) Wholly owned subsidiary of Gilford Instruments Ltd.
All subsidiaries are included in the consolidated financialstatements for 1979.↩
2. In each of its major product areas, Gilford faced competition from both large and small companies. In the clinical analyzer market, Technicon was the market leader. Gilford occupied a second-tier position with Beckman and DuPont. In the research spectrophotometer market, Gilford competed with Beckman. In the diagnostic reagent/disposable area, the dominant force was DuPont and Technicon. In this market, Gilford competed against Dow, Hycel, Dade, Harleco, Worthington Biochemical, Boehringer-Mannheim, General Diagnostics, and Hyland.↩
3. On July 31, 1979, there were 1,660,499 shares outstanding, and the parties stipulated that petitioner's block represented approximately 22.98 percent of the Gilford shares outstanding. The correct percentage is 22.95 percent. On Nov. 16, 1979, the block represented approximately 22.90 percent.↩
4. In November of 1979, NASDAQ market makers for Gilford stock were Merrill Lynch, the Ohio Co., Prescott Ball & Turben, Shearson Hayden Stone, Inc., Bache Halsey Stuart, Amswiss International, Wm. C. Rooney & Co., and Cantor Fitzgerald & Co.↩
5. The board voted to elect Bronson P. Clark as the new chairman of the board.↩
6. The market quotations of Gilford stock dropped to a yearly low of 10 1/4 bid price on Monday, Nov. 19, 1979, presumably reflecting the death of decedent. Thus, Joyce noted that an adjustment for decedent's death existed in the mean figures used to reach the $ 11.31 market price on Nov. 17, 1979.↩
7. The monthly volume for Gilford common stock from December 1978 to November 1979 is noted in the text
8. The Securities and Exchange Commission considered decedent to be a "parent" of Gilford for securities law purposes. As a result, decedent's and petitioner's Gilford stock was a restricted security as defined by the Securities and Exchange Commission's rule 144.↩
9. Joyce noted that Gilford stock had an average weekly trading volume of 14,000 shares. Therefore, the willing buyer of this block of stock could sell 14,000 shares of stock every 3 months under rule 144. At this rate, decedent's 381,150 shares would not be disposed of for 7 years.↩
10. These companies are industrial stock companies and are as follows: American Nuclear Corp., Analog Devices, Inc., Arnav Industries, Inc., Chemical & Pollution Sciences, Inc., Giffen Industries, Inc., Interfashion, Inc., Jewelcor, Inc., Miles-Samuelson, Inc., National Computer Corp., Parker Drilling Co., the Service Group, Inc., TBS Computer Centers Corp., the Valtronic Corp., and Volt Information Sciences, Inc.
In order to be a "comparable" company, Joyce established the following criteria with which each company's stock had to comply: (1) The company did not experience an earnings deficit in either of the 2 fiscal years preceding the acquisition of its restricted stock; (2) the company must have been in business for at least 3 fiscal years prior to the acquisition of its restricted stock; (3) there must be sufficient public financial data available concerning the company so that the public market is a well informed one; and (4) there was an active market for the company's stock at the time of the acquisition of the restricted shares.↩
11. Joyce believed that the ability to have a successful public offering of industrial stock was somewhat difficult in the 1980 market and that the 33-percent discount may be too low. However, the attractiveness of Gilford in the technological field would offset this disadvantage. Joyce also noted that the NASDAQ index was in decline for 6 weeks prior to the valuation date.↩
12. As the discount for the restricted nature of the stock centered on a 33-percent figure, the 2-percent increase must reflect Joyce's additional discount for blockage.↩
13. Unless otherwise indicated, section references are to the Internal Revenue Code of 1954 as amended and in effect at the date of the decedent's death.↩
14.
15. See
16.
17. As respondent has recognized in
"Valuation of securities is, in essence, a prophesy as to the future and
18. The facts presented by these documents go to the weight of the evidence, not its admissibility.
19. We note that directors have a fiduciary duty to act in the best interests of the corporation and its shareholders.
20. We note that in a Memorandum Opinion this Court has held that in valuing over-the-counter stock of a corporation, the merger of the corporation approximately 1 year after decedent's death should not be taken into account in valuing the shares. There had not been any meeting of the minds or agreement on the terms of merger, no pending merger negotiations, no public knowledge, and no rumors as to any merger negotiations on the valuation date.
We have examined the cases cited by respondent and find them to be inapplicable to the facts of this case. While in
21. See
22. See
23. As
24. See
25. We also note that decedent's death depressed the bid and asked prices on the Monday following his death. The blockage discount should not duplicate the market's own discount. See
26. See note 8
27. In cases which involve closely held stock with no sales or market quotations, such an approach may present a greater difficulty given the mandate of
28. For example, Bio-Medical Science, Inc., had insufficient financial data. National Hospital Corp. had no recent information. Other companies had deficits in prior years or an inactive market. Thus, there was not sufficient information to compare.↩
29. In evaluating the financial position of Gilford, Kidder, Peabody compared its common stock to selected analytical manufacturers. Beckman and Technicon were traded on the New York Stock Exchange. Galman Sciences was traded on the American Stock Exchange. Finnigan Corp., Instrumentation Laboratory, and Nicolet Instrument were traded over the counter. Near the date of decedent's death, these over-the-counter stocks carried bid quotations of 14, 13 1/2, and 19 7/8, respectively. Despite the fact that Joyce did not use these three over-the-counter stocks as comparable stocks, we believe that the discount is valid given the restricted nature of petitioner's stock.↩
30. See Securities and Exchange Commission, Institutional Investor Study Report, H. Doc. 92-64, Vol. 5, 92d Cong., 1st Sess. (1971).↩
31. In fact, the study found that only 37 percent of restricted stocks traded over the counter were purchased at discounts not exceeding 20 percent. See Institutional Investor Study Report,
32. Institutional Investor Study Report,
33. "Nothing astonishes man so much as common sense and plain dealing," quoting R. W. Emerson, Essays, "Art," in Bartlett's Familiar Quotations 497 (15th ed. 1980).
amerada-hess-corporation-successor-by-merger-to-hess-oil-chemical , 517 F.2d 75 ( 1975 )
United States v. Cartwright , 93 S. Ct. 1713 ( 1973 )
American Pipe & Steel Corporation v. Commissioner of ... , 243 F.2d 125 ( 1957 )
Estate of J. A. Kreis, Deceased, Herbert Clark, Executors v.... , 227 F.2d 753 ( 1955 )
Maxe Colleen McCorkle Morris v. Commissioner of Internal ... , 761 F.2d 1195 ( 1985 )
Helvering v. National Grocery Co. , 58 S. Ct. 932 ( 1938 )
Seymour Silverman v. Commissioner of Internal Revenue , 538 F.2d 927 ( 1976 )
Jack E. Golsen and Sylvia H. Golsen v. Commissioner of ... , 445 F.2d 985 ( 1971 )
Michael L. Rockwell, and Regina Rockwell v. Commissioner of ... , 512 F.2d 882 ( 1975 )
Estate of Thomas L. Kaplin, Deceased, Maury I. Kaplin, and ... , 90 A.L.R. Fed. 395 ( 1984 )
Willard Barry and Harriet Barry v. United States , 501 F.2d 578 ( 1974 )
J. Clark Akers, Iii, Eleanor M. Akers, William B. Akers, ... , 798 F.2d 894 ( 1986 )
Guggenheim v. Helvering , 117 F.2d 469 ( 1941 )
pulte-home-corporation-pulte-land-of-illinois-corporation-pulte-land-of , 771 F.2d 183 ( 1985 )
Lewis Thurston Anderson and Clyde Velma Anderson, Lewis ... , 250 F.2d 242 ( 1957 )
Mildred E. Walter, Executors De Bonis Non of the Estate of ... , 341 F.2d 182 ( 1965 )
Maytag v. Commissioner of Internal Revenue , 187 F.2d 962 ( 1951 )
Ithaca Trust Co. v. United States , 49 S. Ct. 291 ( 1929 )
Welch v. Helvering , 54 S. Ct. 8 ( 1933 )